Pharmaceuticals, Biotechnology and Life Sciences
U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
Premaitha Health PLC, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.
Allergan plc and Ironwood Pharmaceuticals, Inc. have announced that Allergan has acquired rights to Constella (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to Linzess (linaclotide) in Mexico from Almirall.
Food and Drug Administration (FDA) has approved YONDELIS (trabectedin) for the treatment of patients with unresectable (unable to be removed…
The percentage of Americans who reported using marijuana in the past year more than doubled between 2001-2002 and 2012-2013, and the increase in marijuana use disorder during that time was nearly as large.
Secretary of U.S. Department of Health & Human Services (HSS) Sylvia M. Burwell on Tuesday announced six new members to serve on the Advisory Council on Alzheimer’s Research, Care, and Services.
“We were disappointed, but will soon have data from the Phase 3 study, OPUS 3,” said Flemming Ornskov, M.D., CEO, Shire.
Blood thinner (anticoagulant) can reduce the risk of a stroke by 50% to 60% for people who have atrial fibrillation.
The U.S. Food and Drug Administration on Friday granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
“These findings may help inform specialists treating patients with overactive bladder, that BOTOX is an effective and safe treatment option for patients not getting the relief from an anticholinergic.”